GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » EBITDA Margin %

Bangkok Genomics Innovation PCL (BKK:BKGI) EBITDA Margin % : 18.89% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bangkok Genomics Innovation PCL's EBITDA for the three months ended in Dec. 2024 was ฿18.1 Mil. Bangkok Genomics Innovation PCL's Revenue for the three months ended in Dec. 2024 was ฿95.8 Mil. Therefore, Bangkok Genomics Innovation PCL's EBITDA margin for the quarter that ended in Dec. 2024 was 18.89%.


Bangkok Genomics Innovation PCL EBITDA Margin % Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL EBITDA Margin % Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial 16.25 30.35 30.93 20.19 20.78

Bangkok Genomics Innovation PCL Quarterly Data
Dec19 Dec20 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.09 20.69 21.33 22.39 18.89

Competitive Comparison of Bangkok Genomics Innovation PCL's EBITDA Margin %

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bangkok Genomics Innovation PCL's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's EBITDA Margin % falls into.


;
;

Bangkok Genomics Innovation PCL EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bangkok Genomics Innovation PCL's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=70.168/337.593
=20.78 %

Bangkok Genomics Innovation PCL's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=18.089/95.77
=18.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bangkok Genomics Innovation PCL  (BKK:BKGI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Bangkok Genomics Innovation PCL EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bangkok Genomics Innovation PCL Business Description

Traded in Other Exchanges
N/A
Address
3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Scientific testing services which generates key revenue, and Sale of goods.

Bangkok Genomics Innovation PCL Headlines